Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Industry veteran to lead Brinton’s expansion across India and key Asia Pacific markets
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Subscribe To Our Newsletter & Stay Updated
